New and updated clinical data presented by biopharma firms at the International Association for the Study of Lung Cancer, 2023 World Conference on Lung Cancer, including: Astrazeneca, Daiichi.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Adel, Astellas, Aston, Astrazeneca, Bioray, Biosyngen, Daiichi Sankyo, Dizal, Innocare, Oscotec, Takeda.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: 2seventy, Aclipse, Beigene, Bionomics, Chong Kun Dang, Hasten, Lib, JW, Merck & Co., Nona, Pharmazz, PT Kalbe Farma, PT Kalbe Genexine, Salipro, Shanghai Henlius, Sumitomo, Sun.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Asieris, Caliway, Foresee, Hutchmed, Innocare, J Ints, Sinovac,Takeda, Urovant.

Biopharmas in Asia-Pacific raising money in public or private financings: Brim, Recce.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Arcturus, Astrazeneca, CSL Seqirus, Gloria, Neurophth.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Biocytogen, Chr. Hansen, Imidomics, Myricx, Novartis, Novozymes, Samsung Bioepis, Sandoz, Sinovac, Tnax.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: ACM Biolabs.

Biopharmas in Asia-Pacific raising money in public or private financings: Aptose, Grit, Hanmi, Jiangsu Nhwa, Trevena.